Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENLIUS (02696.HK): HLX17 Completes First Patient Dosing in US for International Multi-center Phase 1 Clinical Trial
Recommend 0 Positive 2 Negative 0 |
||||
|
||||
|
HENLIUS (02696.HK) announced that its self-developed pembrolizumab biosimilar HLX17 (recombinant anti-PD-1 humanized monoclonal antibody injection) has recently completed dosing of the first patient in the United States in an international multi-center Phase 1 clinical trial conducted in patients with various resected solid tumors. The Phase 1 clinical trial is also being carried out simultaneously in China (excluding Hong Kong, Macau and Taiwan). (sl/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
